Article
The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation.
Human cell - 1 Jul 2026
Jiang Lei, Luo Yiming, Liang Huan, Feng Xujiao, Huang Yan, Li Yanyan, Wang Zhenghang, Xu Ting, Zou Heng, Li Zhi, Shen Lin, Chen Yang, Wang Weihu, Li Jian
Abstract excerpt
The Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most frequently mutated oncogenes and is associated with poor prognosis. Long considered an undruggable target, KRAS has recently become actionable with the development of direct inhibitors, particularly against the G12C mutation. Our group previously reported promising efficacy and safety results for glecirasib (JAB-21822), a novel KRASG12C...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.